Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Quick links
Contact us

1234 5678

PO Box 3787

South Brisbane QLD 4101
Become a patient

Dr Andrew Oar

BSc, MBBS, MIPH, FRANZCR

  • Radiation Oncologist
Become a patient Refer a patient
Gold Coast Private
07 5634 2400 07 5634 2401
admin.goldcoastprivate@icon.team
Dr Andrew Oar | Icon Cancer Centre

Biography

I am committed to delivering a comprehensive oncology service to my patients, utilising contemporary evidence-based practice.

Dr Andrew Oar is a radiation oncologist at Icon Cancer Centre Gold Coast. He completed his postgraduate medical training at the University of Queensland in 2010 and subsequently completed a Masters of International Public Health (MIPH) in 2011. He completed the majority of his specialist training at Liverpool and Campbelltown Hospitals in Sydney. He underwent a fellowship in lung and gastrointestinal cancer as well as stereotactic radiation therapy. Dr Oar completed his specialist radiation oncology examinations in August 2016, and became a fellow of the Royal Australian and New Zealand College of Radiologists (FRANZCR) in May 2018.

Dr Oar has presented his research work into pancreatic cancer and magnetic resonance imaging (MRI) at both national and international conferences. He is an executive member of the Asia Pacific Radiation Oncology Special Interest Group (APROSIG) and conjoint lecturer at the University of New South Wales (UNSW) and University of Western Sydney (UWS).

He is currently the clinical research lead at Icon Cancer Centre Gold Coast and is actively involved in several clinical trials. He is the principal investigator of the MASTERPLAN trial – a national randomised clinical trial of the Australasian Gastrointestinal Trials Group (AGITG) investigating stereotactic radiation therapy and chemotherapy treatment for pancreatic cancer. His areas of interest include breast cancer, gastrointestinal cancer, skin cancer, lung cancer, genitourinary cancer and stereotactic radiation therapy.

Publications

Research

Trials being conducted by this doctor

PRIME_LUNG

Outcome for patients diagnosed with advanced lung cancer remains poor; alternative treatment options are urgently needed. Studies in other metastatic cancers indicate radiotherapy to the primary tumour can improve outcomes. The investigators postulate this will also be observed in lung cancer patients. The aim of this pilot study is to assess the safety and feasibility of stereotactic ablative radiotherapy (SABR) to the lung primary prior to standard of care (SoC) systemic therapy in advanced non-small cell lung cancer (NSCLC). Forty patients with advanced (Stage IV) NSCLC will be recruited across the five Peter Mac campuses. Patients will be randomised to receive SoC systemic therapy with or without radiotherapy to the lung primary. Radiotherapy will be delivered before cycle 3 of SoC systemic therapy. Biospecimens will be collected for future translational research. The primary outcome of the study (feasibility of the protocol) will be assessed by the ability to deliver radiotherapy to the lung cancer primary, whilst meeting dose constraints. The study will also 1) evaluate proportion of patients who are willing to be randomised; 2) describe toxicity during the follow up period in each arm; 3) describe progression free survival.

Locations Gold Coast University Hospital

Diagnosis Lung cancer

Open for recruitment